Eli Lilly (LLY) announced “positive” results from a Phase 2b trial evaluating the safety and efficacy of EloraTZP. Eloralintide alone reduced body ...
Source Link- Like
- Comment
- Favorite
Lilly says participants on EloraTZP lost up to average 23.3% of weight in study
TIPRANKS09-30 22:25
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Like
Report
Login to post
No comments yet